Topic: lung cancer


7. Tagrisso

In its fourth full year in the extremely lucrative lung cancer market, AstraZeneca's Tagrisso outperformed analysts' expectations and emerged as the standard-of-care option in one of its two approved indications. But all that success comes at a price—continued growth—and AstraZeneca could soon see its drug peak.